Efficacy and Safety of Insulin Aspart in Subjects With Type 1 or Type 2 Diabetes

• Status: Completed
• Trial end date: 2005-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial is conducted in Asia. The aim of this trial is to compare the efficacy of postprandial plasma glucose of two treatment regimens in Chinese subjects.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Insulin; Insulin Aspart; Insulin degludec, insulin aspart drug combination; Insulin, Globin Zinc; Insulin, Isophane; Insulin, Long-Acting; Isophane insulin, beef; Isophane Insulin, Human

Criteria

Inclusion Criteria:

• Type 1 or 2 diabetes for at least 4 weeks

• Treatment with oral antidiabetic drugs (OADs) and/or insulin for at least 4 weeks

• HbA1c: 7.5-13.5%

• Body Mass Index (BMI): 18-35 kg/m2

Exclusion Criteria:

• Treatment with either soluble human insulin or insulin NPH three times daily within 3 months before trial participation

• History of drug abuse or alcohol dependence